493 related articles for article (PubMed ID: 29526608)
1. The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): Rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression.
Okereke OI; Reynolds CF; Mischoulon D; Chang G; Cook NR; Copeland T; Friedenberg G; Buring JE; Manson JE
Contemp Clin Trials; 2018 May; 68():133-145. PubMed ID: 29526608
[TBL] [Abstract][Full Text] [Related]
2. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease.
Manson JE; Bassuk SS; Lee IM; Cook NR; Albert MA; Gordon D; Zaharris E; Macfadyen JG; Danielson E; Lin J; Zhang SM; Buring JE
Contemp Clin Trials; 2012 Jan; 33(1):159-71. PubMed ID: 21986389
[TBL] [Abstract][Full Text] [Related]
3. Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial.
Okereke OI; Vyas CM; Mischoulon D; Chang G; Cook NR; Weinberg A; Bubes V; Copeland T; Friedenberg G; Lee IM; Buring JE; Reynolds CF; Manson JE
JAMA; 2021 Dec; 326(23):2385-2394. PubMed ID: 34932079
[TBL] [Abstract][Full Text] [Related]
4. Lung VITAL: Rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega-3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults.
Gold DR; Litonjua AA; Carey VJ; Manson JE; Buring JE; Lee IM; Gordon D; Walter J; Friedenberg G; Hankinson JL; Copeland T; Luttmann-Gibson H
Contemp Clin Trials; 2016 Mar; 47():185-95. PubMed ID: 26784651
[TBL] [Abstract][Full Text] [Related]
5. Effects of Vitamin D
Vyas CM; Mischoulon D; Chang G; Cook NR; Weinberg A; Copeland T; Kang JH; Bubes V; Friedenberg G; LeBoff MS; Lee IM; Buring JE; Manson JE; Reynolds CF; Okereke OI
J Clin Psychiatry; 2023 Jun; 84(4):. PubMed ID: 37378490
[No Abstract] [Full Text] [Related]
6. Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial.
Okereke OI; Reynolds CF; Mischoulon D; Chang G; Vyas CM; Cook NR; Weinberg A; Bubes V; Copeland T; Friedenberg G; Lee IM; Buring JE; Manson JE
JAMA; 2020 Aug; 324(5):471-480. PubMed ID: 32749491
[TBL] [Abstract][Full Text] [Related]
7. VITAL-Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega-3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA-3 TriaL (VITAL).
LeBoff MS; Yue AY; Copeland T; Cook NR; Buring JE; Manson JE
Contemp Clin Trials; 2015 Mar; 41():259-68. PubMed ID: 25623291
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D and omega-3 trial to prevent and treat diabetic kidney disease: Rationale, design, and baseline characteristics.
de Boer IH; Zelnick LR; Lin J; Schaumberg D; Wang L; Ruzinski J; Friedenberg G; Duszlak J; Bubes VY; Hoofnagle AN; Thadhani R; Glynn RJ; Buring JE; Sesso HD; Manson JE
Contemp Clin Trials; 2018 Nov; 74():11-17. PubMed ID: 30282055
[TBL] [Abstract][Full Text] [Related]
9. Effect of Vitamin D and ω-3 Fatty Acid Supplementation on Risk of Age-Related Macular Degeneration: An Ancillary Study of the VITAL Randomized Clinical Trial.
Christen WG; Cook NR; Manson JE; Buring JE; Chasman DI; Lee IM; Bubes V; Li C; Haubourg M; Schaumberg DA;
JAMA Ophthalmol; 2020 Dec; 138(12):1280-1289. PubMed ID: 33119047
[TBL] [Abstract][Full Text] [Related]
10. Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL).
Bassuk SS; Manson JE; Lee IM; Cook NR; Christen WG; Bubes VY; Gordon DS; Copeland T; Friedenberg G; D'Agostino DM; Ridge CY; MacFadyen JG; Kalan K; Buring JE
Contemp Clin Trials; 2016 Mar; 47():235-43. PubMed ID: 26767629
[TBL] [Abstract][Full Text] [Related]
11. Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL): Effects on Bone Structure and Architecture.
Donlon CM; LeBoff MS; Chou SH; Cook NR; Copeland T; Buring JE; Bubes V; Kotler G; Manson JE
Contemp Clin Trials; 2018 Apr; 67():56-67. PubMed ID: 29408561
[TBL] [Abstract][Full Text] [Related]
12. Effect of Vitamin D3 and Omega-3 Fatty Acid Supplementation on Risk of Frailty: An Ancillary Study of a Randomized Clinical Trial.
Orkaby AR; Dushkes R; Ward R; Djousse L; Buring JE; Lee IM; Cook NR; LeBoff MS; Okereke OI; Copeland T; Manson JE
JAMA Netw Open; 2022 Sep; 5(9):e2231206. PubMed ID: 36098968
[TBL] [Abstract][Full Text] [Related]
13. Serum 25-hydroxyvitamin D in the VITamin D and OmegA-3 TriaL (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatment.
Luttmann-Gibson H; Mora S; Camargo CA; Cook NR; Demler OV; Ghoshal A; Wohlgemuth J; Kulkarni K; Larsen J; Prentice J; Cobble M; Bubes V; Li C; Friedenberg G; Lee IM; Buring JE; Manson JE
Contemp Clin Trials; 2019 Dec; 87():105854. PubMed ID: 31669447
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence.
Manson JE; Bassuk SS; Cook NR; Lee IM; Mora S; Albert CM; Buring JE;
Circ Res; 2020 Jan; 126(1):112-128. PubMed ID: 31895658
[TBL] [Abstract][Full Text] [Related]
15. Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial.
Albert CM; Cook NR; Pester J; Moorthy MV; Ridge C; Danik JS; Gencer B; Siddiqi HK; Ng C; Gibson H; Mora S; Buring JE; Manson JE
JAMA; 2021 Mar; 325(11):1061-1073. PubMed ID: 33724323
[TBL] [Abstract][Full Text] [Related]
16. Update on the Vitamin D and OmegA-3 trial (VITAL).
Pradhan AD; Manson JE
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt B):252-6. PubMed ID: 25864623
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Marine ω-3 Fatty Acid Supplementation vs Placebo in Reducing Incidence of Dry Eye Disease in Healthy US Adults: A Randomized Clinical Trial.
Christen WG; Cook NR; Manson JE; Buring JE; Lee IM; Bubes V; Friedenberg G; Dushkes R; Smith D; Schaumberg DA;
JAMA Ophthalmol; 2022 Jul; 140(7):707-714. PubMed ID: 35679030
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial.
Hahn J; Cook NR; Alexander EK; Friedman S; Walter J; Bubes V; Kotler G; Lee IM; Manson JE; Costenbader KH
BMJ; 2022 Jan; 376():e066452. PubMed ID: 35082139
[TBL] [Abstract][Full Text] [Related]
19. VITamin D and OmegA-3 TriaL (VITAL): Effects of Vitamin D Supplements on Risk of Falls in the US Population.
LeBoff MS; Murata EM; Cook NR; Cawthon P; Chou SH; Kotler G; Bubes V; Buring JE; Manson JE
J Clin Endocrinol Metab; 2020 Sep; 105(9):2929-38. PubMed ID: 32492153
[TBL] [Abstract][Full Text] [Related]
20. The effect of vitamin D and omega-3 fatty acid supplementation on pain prevalence and severity in older adults: a large-scale ancillary study of the VITamin D and OmegA-3 triaL (VITAL).
Soens MA; Sesso HD; Manson JE; Fields KG; Buring JE; Lee IM; Cook NR; Kim E; Bubes V; Dushkes R; Serhan CN; Rathmell JP
Pain; 2024 Mar; 165(3):635-643. PubMed ID: 37878483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]